within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX02_Tryptophan;

model Tryptophan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 5.000000000000001e-07,
    adminDuration = 600,
    adminMass = 2000 / 1000000,
    adminCount = 1,
    Vd = 0.027,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 1200);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tryptophan</td></tr><tr><td>ATC code:</td><td>N06AX02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>2000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>27</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tryptophan is an essential amino acid used as a dietary supplement and formerly as an antidepressant or sleep aid. It is a precursor for serotonin and melatonin biosynthesis. Its use as a drug has declined due to safety concerns related to eosinophilia–myalgia syndrome in contaminated batches. It is not widely approved as a prescription medication today but is available as a supplement.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for oral L-tryptophan (dose: 2 g) in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Lalanne, S, et al., &amp; Tordjman, S (2021). Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. <i>International journal of molecular sciences</i> 22(3) –. DOI:<a href=\"https://doi.org/10.3390/ijms22031490\">10.3390/ijms22031490</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33540815/\">https://pubmed.ncbi.nlm.nih.gov/33540815</a></p></li><li><p>Nøhr, MK, et al., &amp; Nielsen, CU (2015). Is oral absorption of vigabatrin carrier-mediated?. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 69 10–18. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2014.12.018\">10.1016/j.ejps.2014.12.018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25562534/\">https://pubmed.ncbi.nlm.nih.gov/25562534</a></p></li><li><p>Kumar, S, et al., &amp; Mautino, MR (2020). Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. <i>European journal of medicinal chemistry</i> 198 112373–None. DOI:<a href=\"https://doi.org/10.1016/j.ejmech.2020.112373\">10.1016/j.ejmech.2020.112373</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32422549/\">https://pubmed.ncbi.nlm.nih.gov/32422549</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AX02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tryptophan;
